Enfusion, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
292812104
SEDOL
BLB56Z7
CIK
0001868912
www.enfusion.com
LEI:
©
Enfusion is a Member of Themefolio
          Financial Markets Support          
FIGI: BBG012MBFQD7
ENFN
Enfusion, Inc.
GICS: - · Sector: Technology · Sub-Sector: Software - Application
AI
PROFILER
NAME
Enfusion, Inc.
ISIN
US2928121043
TICKER
ENFN
MIC
XNYS
REUTERS
ENFN.N
BLOOMBERG
ENFN US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 03.03.2025       Enfusion
US2928121043

Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights: Total revenue was $52.9 million, up 13.9% compared to the same period in the p...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Tue, 25.02.2025       Enfusion
US2928121043

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock is fair to Enfusion shareholders. Halper Sadeh encourages Enfusion shareholders to click here to learn more about their legal ri...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Tue, 14.01.2025       Enfusion
US2928121043

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics Holdings, Inc. (NYSE: CWAN). Under the terms of the proposed transaction, shareholders of Enfusion will receive $5.85 in cash and $5.40 in ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Mon, 13.01.2025       Enfusion
US2928121043

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Enfusion, Inc. (“Enfusion” or “the Company”) (NYSE: ENFN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Enfusion board brea...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Mon, 13.01.2025       Enfusion
US2928121043

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Enfusion, Inc. (NYSE: ENFN) to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock is fair to Enfusion shareholders. Halper Sadeh encourages Enfusion shareholders to click here to learn more about their legal ri...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Mon, 13.01.2025       Enfusion
US2928121043

Ademi LLP is investigating Enfusion (NYSE: ENFN) for possible breaches of fiduciary duty and other violations of law in its transaction with Clearwater. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In t...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Wed, 20.11.2024       Enfusion
US2928121043

Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced that Enfusion’s Chief Financial Officer, Brad Herring, and Chief Operating Officer, Neal Pawar, will participate at the following investor events: Wells Fargo 8th Annual TMT Summit on Tuesday, December ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Mon, 04.11.2024       Enfusion
US2928121043

Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its third quarter 2024 financial results as part of its Q3 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 3Q24 ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.10.2024       Enfusion
US2928121043

Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the appointments of Arman Artuc to Head of Engineering and Jesper Cordes to Head of Client Services Americas. These additions to the leadership team reinforce the company’s position as a global leader in i...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
Thu, 03.10.2024       Enfusion
US2928121043

Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its third quarter 2024 financial results before the U.S. financial markets open on Monday, November 4, 2024. Management will host a conference call and webcast that same morning at 8:30 AM ...
Read More
Enfusion
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S